The March 20th issue of The New England Journal of Medicine includes an article from the Office of New Drugs of the FDA on a topic The Medical Letter reviewed in its August 5, 2013 issue: the FDA’s approval of Diclegis, a fixed-dose combination of the H1-antihistamine doxylamine and the vitamin B6 analog pyridoxine, for […]